To address these problems, PATH focused on developing a thermostable COVID-19 vaccine formulation in product formats—both liquid and dry–that are thermotolerant (i.e., do not require ultra-cold storage or continuous extended refrigeration). Using stabilizing ingredients with verified safety profiles that are common in other established vaccines, will allow the heat-stable formulation to be mass-produced on standard vaccine manufacturing lines.
The findings of this project support storage of a multidose coronavirus vaccine candidate out of the cold chain, simplifying transport and distribution logistics, potentially reducing the overall cost and enabling more equitable access to vaccines.
Key outcomes includes the development of two vaccine product formats (liquid and dry) using thermostable formulations from a New Castle Disease Virus (NDC) vector-based COVID-19 vaccine candidate, NDV-HXP-S—developed by Icahn School of Medicine at Mount Sinai and University of Texas at Austin and manufactured by Instituto Butantan. This vaccine candidate has already demonstrated efficacy in preclinical studies and acceptable safety and potent immunogenicity in clinical studies.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
PATH Center for Vaccines Innovation & Access